FMP
ANI Pharmaceuticals, Inc.
ANIP
NASDAQ
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
70.69 USD
-0.13 (-0.184%)
Historical Prices
From:
To:
About
ceo
Mr. Nikhil Lalwani
sector
Healthcare
industry
Drug Manufacturers - Specialty & Generic
exchange
NASDAQ
Description
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and...
CIK
0001023024
ISIN
US00182C1036
CUSIP
00182C103
Address
210 Main Street West
Phone
218 634 3500
Country
US
Employee
897
IPO Date
May 5, 2000
Financial Statement
Earnings
ANIP Financial Summary
CIK
0001023024
Exchange
NASDAQ
Industry
Drug Manufacturers -...
Sector
Healthcare
CUSIP
00182C103
ISIN
US00182C1036
Country
US
Price
70.69
Beta
0.49
Volume Avg.
347.19k
Market Cap
1.53B
Shares
-
52-Week
52.5-72.57
DCF
-55.94
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-67.97
P/B
-
Website
https://www.anipharmaceuticals.com
Upgrades and Downgrades
We are unable to load the data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest ANIP News
Rayan Ahmad
Apr 14, 2025
ANI Pharmaceuticals Inc (NASDAQ:ANIP) Insider Sale and Marke...
ANI Pharmaceuticals Inc (NASDAQ:ANIP) is a specialty pharmaceutical company that develops, manufactures, and markets branded and generic prescription pharmaceuticals. The company focuses on niche markets and complex products, which sets it apart from larger pharmaceutical companies. ANI competes with other specialty pharmaceutical firms, striving to maintain a strong market position through strategic product development and acquisitions. On April 14, 2025, Cook Meredith, Senior Vice President, ...
Zacks Investment Research
Aug 15, 2024
Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks Investment Research
Aug 6, 2024
Compared to Estimates, ANI (ANIP) Q2 Earnings: A Look at Key...
The headline numbers for ANI (ANIP) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks Investment Research
Aug 6, 2024
ANI Pharmaceuticals (ANIP) Tops Q2 Earnings and Revenue Esti...
ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $1.02 per share, beating the Zacks Consensus Estimate of $0.93 per share. This compares to earnings of $1.28 per share a year ago.
Seeking Alpha
Aug 2, 2024
ANI Pharmaceuticals: Tezruly Just Approved, 2 More NDAs Unde...
ANIP has three 505(b)(2) NDA submissions under FDA review, including oral liquid terazosin, female testosterone drug, and oral liquid hydrochlorothiazide. Potential peak sales for Tezruly and hydrochlorothiazide in the US could exceed $500 million, while the female testosterone drug could generate $290 million in royalties. ANIP's revenue could reach $1.41 billion in sales and $290 million in royalties by 2028, with significant growth potential.
Seeking Alpha
Jun 10, 2024
ANI Pharmaceuticals Is Undervalued, As Royalty Potential Is ...
ANIP's potential royalty revenue from two upcoming drug applications could generate $415 million annually, not reflected in the current share price. ANI Pharmaceuticals' legal action against CG Oncology could result in royalties for Cretostimogene, potentially adding $125 million per year. The Company's female testosterone drug could generate royalties of $290 million per year, with potential for additional indications and international sales.
GlobeNewsWire
May 29, 2024
ANI Pharmaceuticals to Present at the 2024 Jefferies Global ...
BAUDETTE, Minn., May 29, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will present at the 2024 Jefferies Global Healthcare Conference in New York City as follows:
Zacks Investment Research
May 20, 2024
Down -6.19% in 4 Weeks, Here's Why ANI (ANIP) Looks Ripe for...
ANI (ANIP) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
